» Articles » PMID: 35533076

Central Visual Function and Genotype-Phenotype Correlations in PDE6A-Associated Retinitis Pigmentosa

Abstract

Purpose: Autosomal recessive retinitis pigmentosa (arRP) can be caused by mutations in the phosphodiesterase 6A (PDE6A) gene. Here, we describe the natural course of disease progression with respect to central retinal function (i.e., visual acuity, contrast sensitivity, and color vision) and establish a detailed genotype--phenotype correlation.

Methods: Forty-four patients (26 females; mean age ± SD, 43 ± 13 years) with a confirmed genetic diagnosis of PDE6A-associated arRP underwent comprehensive ophthalmological examinations including best-corrected visual acuity (BCVA) with Early Treatment Diabetic Retinopathy Study charts, contrast sensitivity (CS) with Pelli-Robson charts at distances of 3 m and 1 m, and color vision testing using Roth 28-Hue and Panel D-15 saturated color cups.

Results: The most frequently observed variants were c.998+1G>A/p.?, c.304C>A/p.R102S, and c.2053G>A/p.V685M. Central retinal function in patients homozygous for variant c.304C>A/p.R102S was better when compared to patients homozygous for variant c.998+1G>A/p.?, although the former were older at baseline. Central retinal function was similar in patients homozygous for variant c.304C>A/p.R102S and patients heterozygous for variants c.304C>A/p.R102S and c.2053G>A/p.V685M, although the latter were younger at baseline. Annual decline rates in central retinal function were small.

Conclusions: We conclude that the severity of the different disease-causing PDE6A mutations in humans with respect to central visual function may be ranked as follows: c.2053G>A/p.V685M in homozygous state (most severe) > c.998+1G>A/p.? in homozygous state > c.304C>A/p.R102S and c.2053G>A/p.V685M in compound-heterozygous state > c.304C>A/p.R102S in homozygous state (mildest). The assessment of treatment efficacy in interventional trials will remain challenging due to small annual decline rates in central retinal function.

Citing Articles

All-in-one AAV-mediated Nrl gene inactivation rescues retinal degeneration in Pde6a mice.

Liu Z, Chen S, Lo C, Wang Q, Sun Y JCI Insight. 2024; 9(24).

PMID: 39499900 PMC: 11665581. DOI: 10.1172/jci.insight.178159.


Efficient Rescue of Retinal Degeneration in Pde6a Mice by Engineered Base Editing and Prime Editing.

Liu Z, Chen S, Davis A, Lo C, Wang Q, Li T Adv Sci (Weinh). 2024; 11(42):e2405628.

PMID: 39297417 PMC: 11558111. DOI: 10.1002/advs.202405628.


Self-Reported Functional Vision in USH2A-Associated Retinal Degeneration as Measured by the Michigan Retinal Degeneration Questionnaire.

Parekh B, Duncan J, Samarakoon L, Melia M, Abalem M, Andrews C Invest Ophthalmol Vis Sci. 2024; 65(6):5.

PMID: 38833260 PMC: 11156206. DOI: 10.1167/iovs.65.6.5.


Electrically-evoked responses for retinal prostheses are differentially altered depending on ganglion cell types in outer retinal neurodegeneration caused by gene mutation.

Roh H, Otgondemberel Y, Eom J, Kim D, Im M Front Cell Neurosci. 2023; 17:1115703.

PMID: 36814867 PMC: 9939843. DOI: 10.3389/fncel.2023.1115703.

References
1.
Tuntivanich N, Pittler S, Fischer A, Omar G, Kiupel M, Weber A . Characterization of a canine model of autosomal recessive retinitis pigmentosa due to a PDE6A mutation. Invest Ophthalmol Vis Sci. 2008; 50(2):801-13. PMC: 3720143. DOI: 10.1167/iovs.08-2562. View

2.
Sharon D, Ben-Yosef T, Goldenberg-Cohen N, Pras E, Gradstein L, Soudry S . A nationwide genetic analysis of inherited retinal diseases in Israel as assessed by the Israeli inherited retinal disease consortium (IIRDC). Hum Mutat. 2019; 41(1):140-149. DOI: 10.1002/humu.23903. View

3.
Csaky K, Richman E, Ferris 3rd F . Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci. 2008; 49(2):479-89. DOI: 10.1167/iovs.07-1132. View

4.
Kong X, Fujinami K, Strauss R, Munoz B, West S, Cideciyan A . Visual Acuity Change Over 24 Months and Its Association With Foveal Phenotype and Genotype in Individuals With Stargardt Disease: ProgStar Study Report No. 10. JAMA Ophthalmol. 2018; 136(8):920-928. PMC: 6142940. DOI: 10.1001/jamaophthalmol.2018.2198. View

5.
Yang Y, Dunbar H . Clinical Perspectives and Trends: Microperimetry as a Trial Endpoint in Retinal Disease. Ophthalmologica. 2021; 244(5):418-450. PMC: 8686703. DOI: 10.1159/000515148. View